The extract of Agathis robusta as an antifungal agent is prepared by hydrodistillation of the powdered bark of A. robusta in a Clevenger-type apparatus at 100 C. for 6 hours to obtain the essential oils of A. robusta. The essential oil is mixed with an ointment base of cholesterol, liquid paraffin, lanolin, and vaseline album, the powdered essential oil of A. robusta being added to the ointment base at 1 or 2% w/w and homogenized to a smooth ointment. When tested in vivo on Wistar rats topically infected with Candida albicans, both the 1% and 2% ointment formulations demonstrated substantial antifungal activity.

It is an object of the present invention to provide a composition for improving intestinal flora. The composition for improving intestinal flora includes gnetin C and/or a glycoside thereof for proliferating Akkermansia having an effect of improving the intestinal flora.

The present disclosure relates to a composition for preventing or treating lung cancer, comprising a compound isolated from a Cephalotaxus extract as an active ingredient. Isoharringtonine, which is the compound isolated from the Cephalotaxus extract according to the present disclosure, induces apoptosis and exhibits the effect of inhibiting the growth of non-small cell lung cancer cell lines, and thus can be useful in the prevention or treatment of lung cancer.

In addition, the combined treatment of isoharringtonine and siNR4A1 enhances anticancer activity, and the combined treatment of isoharringtonine and cisplatin, which is a conventional anticancer drug, induces a high anticancer effect at a low concentration of cisplatin, thereby reducing side effects of anticancer treatment.

The present disclosure relates to a composition for preventing or treating lung cancer, comprising a compound isolated from a Cephalotaxus extract as an active ingredient. Isoharringtonine, which is the compound isolated from the Cephalotaxus extract according to the present disclosure, induces apoptosis and exhibits the effect of inhibiting the growth of non-small cell lung cancer cell lines, and thus can be useful in the prevention or treatment of lung cancer.

In addition, the combined treatment of isoharringtonine and siNR4A1 enhances anticancer activity, and the combined treatment of isoharringtonine and cisplatin, which is a conventional anticancer drug, induces a high anticancer effect at a low concentration of cisplatin, thereby reducing side effects of anticancer treatment.

Provided are: a method of producing a therapeutic agent for skin lesions suitable for treatment or prevention of a skin lesion such as a bedsore; and a therapeutic agent for skin lesions produced by the production method. The method of producing a therapeutic agent for skin lesions characterized by including a mixing step of mixing earthworm castings with water and a collecting step of collecting vaporized water generated from a mixture obtained in the mixing step to obtain a liquid; and the therapeutic agent for skin lesions produced by the production method. It is preferred to further mix an organic substance together with the earthworm castings and the water in the mixing step.

Provided are: a method of producing a therapeutic agent for skin lesions suitable for treatment or prevention of a skin lesion such as a bedsore; and a therapeutic agent for skin lesions produced by the production method. The method of producing a therapeutic agent for skin lesions characterized by including a mixing step of mixing earthworm castings with water and a collecting step of collecting vaporized water generated from a mixture obtained in the mixing step to obtain a liquid; and the therapeutic agent for skin lesions produced by the production method. It is preferred to further mix an organic substance together with the earthworm castings and the water in the mixing step.

Provided are: a method for producing a nasal drop composition suitable for treatment or prevention of a disease or symptom in the nasal cavities; and a nasal drop composition produced by the production method. The nasal drop composition production method characterized by including a mixing step of mixing earthworm castings with water and a collecting step of collecting vaporized water generated from a mixture obtained in the mixing step to obtain a liquid; and the nasal drop composition produced by the production method. It is preferred to further mix an organic substance together with the earthworm castings and the water in the mixing step.

Provided are: a method of producing a therapeutic agent for skin lesions suitable for treatment or prevention of a skin lesion such as a bedsore; and a therapeutic agent for skin lesions produced by the production method. The method of producing a therapeutic agent for skin lesions characterized by including a mixing step of mixing earthworm castings with water and a collecting step of collecting vaporized water generated from a mixture obtained in the mixing step to obtain a liquid; and the therapeutic agent for skin lesions produced by the production method. It is preferred to further mix an organic substance together with the earthworm castings and the water in the mixing step.

Provided are: a method of producing a therapeutic agent for skin lesions suitable for treatment or prevention of a skin lesion such as a bedsore; and a therapeutic agent for skin lesions produced by the production method. The method of producing a therapeutic agent for skin lesions characterized by including a mixing step of mixing earthworm castings with water and a collecting step of collecting vaporized water generated from a mixture obtained in the mixing step to obtain a liquid; and the therapeutic agent for skin lesions produced by the production method. It is preferred to further mix an organic substance together with the earthworm castings and the water in the mixing step.

The invention describes a combination of at least one aromatase inhibitor selected from the group of chemical-synthetic aromatase inhibitors and aromatase inhibition exhibiting extracts of soya beans and rapeseed, respectively, and at least one plant extract that contains one or more active ingredient substance(s) extracted from the plant, which is(are) selected from the group of 5? reductase type I and/or type II inhibitors and androgen receptor blockers, said combination being contained for example in a composition and having special properties for influencing hair growth. Uses of this combination are also described.